Pfizer/AstraZeneca and the Public Interest: Do U.K. Foreign Takeover Proposals Prescribe an Effective Remedy?

This article is part of a Chronicle. See more from this Chronicle

David Reader, Oct 15, 2014

When U.S. pharmaceutical giant Pfizer sought to acquire its U.K.-listed counterpart AstraZeneca earlier this year, much discussion centered around the possible adverse impact that the merger could have on the U.K.’s science base, particularly in light of Pfizer’s questionable track record for asset-stripping and cutting investment in Research and Development (“R&D”). Although the proposed £6